EN DE
Watch ABL Bio Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ABL Bio Inc (298380) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of ABL Bio Inc stock KRW 21,656, price KRW 37,450, that is 42.2% below the price, quality 39 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7298380007

AB ABL Bio Inc logo Thin data Nov 10, 2026

ABL Bio Inc

298380 · KQ
Very expensive, weak quality

Our calculation puts a fair price 42% below what the stock costs today.

Low debt
Mixed Growth (revenue 5y +57.8 %/yr in KRW)
Revenue last quarter 74% below a year ago.
Fair value 21,656 KRW · Strongly overvalued
Quality 39/100
Loss-making · -47.6% net margin (FY2025)
Negative free cash flow
Trails peers (2/10)
Narrow moat 16/100
Thin data
Estimate
Watch ABL Bio Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

245,500 KRW 15,530 KRW Fair Value 21,656 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 15,530 KRW – 245,500 KRW · fair‑value band 16,242 KRW – 27,069 KRW · the 37,450 KRW price screens above the 21,656 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow ABL Bio in your weekly email

Every Wednesday you see whether ABL Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.

Show moreShow less

The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor.

It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.

Stock analysis

ABL Bio Inc (298380) currently trades at 37,450 KRW, while our estimate is 21,656 KRW, 42% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 16,242 KRW (bear) to 27,069 KRW (bull), the price of 37,450 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

ABL Bio Inc reported revenue of 79.3B KRW in FY2025 versus 5.3B KRW in FY2021, a compound +96.4%/yr. Reported net income was −37.8B KRW in FY2025.

Key figures

Market cap 2.1T KRW (≈ $1.6B) Small · P/S ratio 66.6 · EPS (TTM) −1,404 KRW · Net margin −47.6% · Return on equity −44.3% · Return on assets (EBIT) −24.2% (5-year average) · Operating margin −85.3% · Revenue (TTM) 34.3B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 85% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −42%, 298380 screens richer than that median.

Fair Value

Bear 16,242 KRW Fair Value 21,656 KRW Bull 27,069 KRW
Price 37,450 KRW · Downside -42.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 90
Are margins and returns getting better?
Cashflow 13
Do the profits arrive as real cash?
Financial strength 91
Debt, balance sheet and risk of trouble
Investment 9
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 16
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+137.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+57.8%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+140.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−736.0% (2020) → −50.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

298380 screens overvalued: fair value 42% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ABL Bio Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside −42.2% · Below median
Profitability
Return on assets −13.5% · Above median
Net margin (12 months) −47.6% · Below median
Operating margin (12 months) −85.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −74.0% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 13.49× · Priciest 25%
P/S (12 months) 60.86× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 298380
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 298380
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 298380
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 298380
argenx SE ARGX $971.55 $908.40 −7% vs 298380
CSL Limited CSL A$201.68 A$181.40 −10% vs 298380
Moderna, Inc MRNA $250.83 $158.70 −37% vs 298380
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 298380
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 298380
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 298380

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ABL Bio Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ABL Bio Inc Fair Value". https://www.fairvalue-calculator.com/stock/298380

Frequently asked questions

Is ABL Bio Inc (298380) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 21,656 KRW versus a price of 37,450 KRW, about 42% lower (overvalued).
What is the fair value of 298380?
Our estimate for ABL Bio Inc is 21,656 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 37,450 KRW.
What is the quality score of 298380?
ABL Bio Inc has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ABL Bio Inc (298380)?
Our calculated price target is the estimate of 21,656 KRW (as of Nov 10, 2026). Cautious scenario 16,242 KRW, optimistic scenario 27,069 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the ABL Bio Inc stock forecast for 2026?
Our estimate puts fair value at 21,656 KRW, about 42% lower versus a price of 37,450 KRW (overvalued). Cautious scenario 16,242 KRW, optimistic scenario 27,069 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ABL Bio Inc (298380)?
ABL Bio Inc reported trailing-twelve-month revenue of about 34.3B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of ABL Bio Inc (298380)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ABL Bio Inc it is 21,656 KRW per share (as of Nov 10, 2026), against a price of 37,450 KRW.
Is ABL Bio Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 298380 trades above its calculated fair value: price 37,450 KRW, fair value 21,656 KRW, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 298380?
No. The price is what the market pays today (37,450 KRW); the fair value is what the company's own numbers justify (21,656 KRW). For ABL Bio Inc the two are 15,794 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ABL Bio Inc worth?
The market values ABL Bio Inc at about 2.1T KRW (market capitalisation, as of Nov 10, 2026). Per share that is 37,450 KRW; our models calculate a fair value of 21,656 KRW per share.
What do the bullish and bearish scenarios say about 298380?
Our models span a range for ABL Bio Inc: cautious scenario 16,242 KRW, base 21,656 KRW, optimistic 27,069 KRW per share (as of Nov 10, 2026, price 37,450 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ABL Bio Inc (298380)?
Balance-sheet figures for ABL Bio Inc (as of Nov 10, 2026): return on equity −44.3%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 298380 from its 52-week high?
ABL Bio Inc trades at 37,450 KRW, about 85% below its 52-week high of 245,500 KRW and 5% above the low of 35,600 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 21,656 KRW is for.
Which stocks are comparable to ABL Bio Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ABL Bio Inc stock attractive at the current price?
The data as of Nov 10, 2026: price 37,450 KRW, calculated fair value 21,656 KRW (−42%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. ABL Bio Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ABL Bio Inc (298380)?
The closing price on Nov 10, 2026 was 37,450 KRW. Our estimate is 21,656 KRW, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ABL Bio Inc right now?
The price sits above even our optimistic bull case (27,069 KRW). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of ABL Bio Inc

How large is the market capitalisation of ABL Bio Inc (298380)?
The market capitalisation of ABL Bio Inc is 2.1T KRW (≈ $1.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ABL Bio Inc (298380)?
The price-to-sales ratio of ABL Bio Inc is 66.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ABL Bio Inc (298380)?
Earnings per share at ABL Bio Inc are −1,404 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ABL Bio Inc (298380)?
The net margin of ABL Bio Inc is −47.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ABL Bio Inc (298380)?
The return on equity (ROE) of ABL Bio Inc is −44.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ABL Bio Inc (298380)?
On an EBIT basis the return on assets of ABL Bio Inc is −24.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ABL Bio Inc (298380)?
The operating margin of ABL Bio Inc is −85.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ABL Bio Inc (298380)?
Revenue at ABL Bio Inc is growing −74.0% versus a year earlier (3y avg +5.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ABL Bio Inc (298380) generate?
The free cash flow of ABL Bio Inc is −61.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ABL Bio Inc (298380) carry?
The net debt of ABL Bio Inc is 14.9B KRW (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ABL Bio Inc in the live analysis

One click puts ABL Bio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.